MA33022B1 - Composition à libération contrôlée pour produire une préparation à libération prolongée contenant de l'udénafil - Google Patents

Composition à libération contrôlée pour produire une préparation à libération prolongée contenant de l'udénafil

Info

Publication number
MA33022B1
MA33022B1 MA33942A MA33942A MA33022B1 MA 33022 B1 MA33022 B1 MA 33022B1 MA 33942 A MA33942 A MA 33942A MA 33942 A MA33942 A MA 33942A MA 33022 B1 MA33022 B1 MA 33022B1
Authority
MA
Morocco
Prior art keywords
produce
odiphenyl
mixture
order
textured
Prior art date
Application number
MA33942A
Other languages
Arabic (ar)
English (en)
Inventor
Moo-Hi Yoo
Bong-Jin Cha
Jeong-Hoon Kim
Sun-Woo Jang
Sang-Dug Han
Original Assignee
Dong Apharm Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dong Apharm Co Ltd filed Critical Dong Apharm Co Ltd
Publication of MA33022B1 publication Critical patent/MA33022B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

LA PRÉSENTE INVENTION CONCERNE UNE COMPOSITION À LIBÉRATION CONTRÔLÉE POUR PRODUIRE UNE PRÉPARATION À LIBÉRATION PROLONGÉE CONTENANT DE L'UDÉNAFIL. PLUS PARTICULIÈREMENT, LA PRÉSENTE INVENTION CONCERNE UNE COMPOSITION À LIBÉRATION CONTRÔLÉE POUR PRODUIRE UNE PRÉPARATION À LIBÉRATION PROLONGÉE CONTENANT DE L'UDÉNAFIL, LADITE COMPOSITION CONTENANT (A) DE L'UDÉNAFIL ET UN SEL PHARMACEUTIQUEMENT ACCEPTABLE, (B) UN MODULATEUR DE SOLUBILITÉ, (C) UN ADSORBANT, ET (D) UN POLYMÈRE HYDROPHILE. LA COMPOSITION À LIBÉRATION CONTRÔLÉE POUR PRODUIRE UNE PRÉPARATION À LIBÉRATION PROLONGÉE CONTENANT DE L'UDÉNAFIL SELON LA PRÉSENTE INVENTION LIBÈRE DES MÉDICAMENTS CONSTAMMENT QUEL QUE SOIT LE NIVEAU DE PH DANS LE TRACTUS GASTRO-INTESTINAL, ET AINSI RÉGULE LIBREMENT LA DURÉE DE LIBÉRATION DE MÉDICAMENT DANS LA PLAGE DE 3 À 24 HEURES, ET RÉDUIT LA VARIABILITÉ DE L'EFFET DE MÉDICAMENTS ENTRE INDIVIDUS. DE PLUS, LA COMPOSITION DE LA PRÉSENTE INVENTION PEUT ÊTRE PRODUITE DANS UNE PRÉPARATION À LIBÉRATION PROLONGÉE QUI A UNE CONDITION OPTIMALE POUR EXPRIMER L'EFFET DE MÉDICAMENTS DANS LE TRAITEMENT DE MALADIES TELLES QUE L'HYPERTENSION ARTÉRIELLE PULMONAIRE, L'HYPERTENSION PORTALE HÉPATIQUE, UNE HYPERPLASIE PROSTATIQUE BÉNIGNE, ET SIMILAIRE, QUI PEUVENT ÊTRE TRAITÉES PAR L'UDÉNAFIL ET QUI REQUIÈRENT L'ADMINISTRATION DE MÉDICAMENTS SUR UNE LONGUE DURÉE. LA COMPOSITION DE LA PRÉSENTE INVENTION PEUT RÉGULER LA LIBÉRATION DE MÉDICAMENTS EN FONCTION DU TEMPS NÉCESSAIRE POUR L'ABSORPTION DE CEUX-CI LORSQUE LESDITS MÉDICAMENTS SONT ADMINISTRÉS À UN CORPS VIVANT, ET AINSI PEUVENT ÊTRE UTILISÉS DE MANIÈRE BÉNÉFIQUE DANS LA PRÉVENTION ET LE TRAITEMENT D'UN TROUBLE DE L'ÉRECTION.
MA33942A 2008-12-17 2009-12-10 Composition à libération contrôlée pour produire une préparation à libération prolongée contenant de l'udénafil MA33022B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020080128499A KR101004205B1 (ko) 2008-12-17 2008-12-17 유데나필 함유 서방성 제제를 제조하기 위한 제어방출 조성물
PCT/KR2009/007382 WO2010071320A2 (fr) 2008-12-17 2009-12-10 Composition à libération contrôlée pour produire une préparation à libération prolongée contenant de l'udénafil

Publications (1)

Publication Number Publication Date
MA33022B1 true MA33022B1 (fr) 2012-02-01

Family

ID=42269213

Family Applications (1)

Application Number Title Priority Date Filing Date
MA33942A MA33022B1 (fr) 2008-12-17 2009-12-10 Composition à libération contrôlée pour produire une préparation à libération prolongée contenant de l'udénafil

Country Status (14)

Country Link
US (1) US20110250279A1 (fr)
EP (1) EP2374479A4 (fr)
JP (1) JP2012512242A (fr)
KR (1) KR101004205B1 (fr)
CN (1) CN102307597A (fr)
AU (1) AU2009327758A1 (fr)
BR (1) BRPI0923003A2 (fr)
CA (1) CA2746190A1 (fr)
MA (1) MA33022B1 (fr)
MX (1) MX2011006450A (fr)
RU (1) RU2480240C2 (fr)
SG (1) SG172084A1 (fr)
WO (1) WO2010071320A2 (fr)
ZA (1) ZA201104445B (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102871997B (zh) * 2011-07-12 2013-11-13 山东绿叶制药有限公司 含有去甲基文拉法辛苯甲酸酯类化合物的缓释药物组合物
EP2919903B1 (fr) 2012-11-14 2020-07-22 W.R. Grace & CO. - CONN. Compositions contenant un matériau biologiquement actif et un oxyde inorganique non ordonné
EP3082428A4 (fr) 2013-12-09 2017-08-02 Respira Therapeutics, Inc. Formulations en poudre d'inhibiteur pde5 et procédés y associés
TN2017000029A1 (en) 2014-08-12 2018-07-04 Mezzion Pharma Co Ltd Methods of improving myocardial performance in fontan patients using udenafil compositions
WO2016168077A1 (fr) * 2015-04-16 2016-10-20 Bpsi Holdings, Llc Compositions d'oxyde de polyéthylène stabilisé
KR102249155B1 (ko) * 2019-07-26 2021-05-07 주식회사 코아팜바이오 유데나필을 함유하는 약제학적 조성물

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR0136527Y1 (ko) 1993-11-30 1999-03-20 이대원 와이어 본딩 헤드
GB9523752D0 (en) 1995-11-21 1996-01-24 Pfizer Ltd Pharmaceutical formulations
US6200604B1 (en) * 1998-03-27 2001-03-13 Cima Labs Inc. Sublingual buccal effervescent
EP2127642A3 (fr) * 1998-08-13 2010-02-24 Cima Labs, Inc. Microémulsions en tant que formes galéniques solides pour administration orale
EA002720B1 (ru) 1998-08-27 2002-08-29 Фармациа Энд Апджон Аб Терапевтическая композиция для введения толтеродина с контролируемым высвобождением и способ лечения мочевого пузыря с её использованием
UA67802C2 (uk) * 1998-10-23 2004-07-15 Пфайзер Рісьоч Енд Дівелепмент Компані, Н.В./С.А. Фармацевтична композиція з контрольованим вивільненням інгібітора цгмф фде-5 (варіанти), спосіб її одержання та спосіб лікування еректильної дисфункції
WO2000054777A1 (fr) * 1999-03-16 2000-09-21 Pentech Pharmaceuticals, Inc. Liberation controlee de sildenafil administre par voie sublinguale ou orale
TWI224966B (en) 1999-11-02 2004-12-11 Pfizer Pharmaceutical composition (I) useful for treating or preventing pulmonary hypertension in a patient
DE60038698T2 (de) 1999-12-23 2009-05-07 Pfizer Products Inc., Groton Hydrogel-gesteuerte dosierungsform
ATE444060T1 (de) * 2001-06-22 2009-10-15 Pfizer Prod Inc Pharmazeutische zusammensetzungen enthaltend dispersionen aus arzneistoffen und neutralen polymeren
JP4547148B2 (ja) 2001-06-22 2010-09-22 ベンド・リサーチ・インコーポレーテッド 非晶質薬剤の吸着物の医薬組成物
KR200270330Y1 (ko) 2001-10-09 2002-04-03 이대범 퍼머용 아이롱
US20050042177A1 (en) 2003-07-23 2005-02-24 Elan Pharma International Ltd. Novel compositions of sildenafil free base
DE102004027743A1 (de) 2004-06-07 2006-01-05 Fresenius Medical Care Deutschland Gmbh Kappe, insbesondere Desinfektionskappe, Detektionsvorrichtung für die Peritonealdialyse, Beutelset für die Peritonealdialyse und dessen Verwendung
WO2006102964A2 (fr) 2005-03-29 2006-10-05 Evonik Röhm Gmbh Forme pharmaceutique multiparticulaire constituee de pellets renfermant une substance ayant un effet modulaire sur la liberation de l'ingredient actif
US20070031349A1 (en) * 2005-06-23 2007-02-08 David Monteith Rapidly absorbing oral formulations of PDE 5 inhibitors
KR100912680B1 (ko) * 2006-03-16 2009-08-19 (주) 벡스코아 제어 방출 제형
KR100792126B1 (ko) 2006-04-04 2008-01-04 동아제약주식회사 피라졸로피리미디논 화합물을 유효성분으로 함유하는전립선 비대증 예방 및 치료제
KR101304343B1 (ko) * 2006-04-06 2013-09-11 한미사이언스 주식회사 Ｐｄｅ-5 억제제의 경구용 속용제형
KR100780479B1 (ko) * 2006-05-08 2007-11-28 윈셋파마 주식회사 이부딜라스트 함유 경구용 제제 및 이의 제조방법
KR100791844B1 (ko) * 2006-06-30 2008-01-07 주식회사유한양행 메트포르민 또는 그의 염을 함유하는 서방성 제제 및 그의제조방법
US20080014257A1 (en) * 2006-07-14 2008-01-17 Par Pharmaceutical, Inc. Oral dosage forms
KR200483492Y1 (ko) 2015-03-31 2017-05-22 산제트 인터내셔널 컴퍼니, 리미티드 공작기계의 지능형 제어 시스템

Also Published As

Publication number Publication date
WO2010071320A2 (fr) 2010-06-24
SG172084A1 (en) 2011-07-28
MX2011006450A (es) 2011-07-28
EP2374479A4 (fr) 2012-09-12
AU2009327758A1 (en) 2011-07-07
KR101004205B1 (ko) 2010-12-24
KR20100069939A (ko) 2010-06-25
EP2374479A2 (fr) 2011-10-12
CN102307597A (zh) 2012-01-04
US20110250279A1 (en) 2011-10-13
ZA201104445B (en) 2012-03-28
BRPI0923003A2 (pt) 2015-12-15
WO2010071320A3 (fr) 2010-09-30
JP2012512242A (ja) 2012-05-31
RU2011129643A (ru) 2013-01-27
CA2746190A1 (fr) 2010-06-24
RU2480240C2 (ru) 2013-04-27

Similar Documents

Publication Publication Date Title
MY153921A (en) Aminopyrazole derivatives
HK1128471A1 (en) Heterocyclic non-nucleoside compounds, their preparation, pharmaceutical composition and their use as antiviral agents
MX2010004576A (es) Derivados de pirimidina novedosos.
MX2010005889A (es) Derivados de tiofeno como agonistas de s1p1/edg1.
DK2321321T3 (da) Triazolo [4,5-d]pyramidinderivater og anvendelse deraf som purinreceptorantagonister
MX2009009597A (es) Derivados de amino-piridina como agonistas del receptor s1p1/edg1.
MX2009007254A (es) Composiciones de tableta en tableta.
MY154909A (en) Novel thiophene derivatives
MY153975A (en) Pyridine derivatives as s1p1/edg1 receptor modulators
WO2007098128A3 (fr) Formules liquides de phényléphrine
MY149869A (en) Thiophene derivatives as s1p1/edg1 receptor agonists
MY153985A (en) Aminotriazole derivatives as alx agonists
IL192948A0 (en) Novel pyridine derivatives
DOP2011000354A (es) Composiciones sublinguales de dexmedetomidina y metodos de uso de ellas
WO2009063222A3 (fr) Compositions solides
MA33022B1 (fr) Composition à libération contrôlée pour produire une préparation à libération prolongée contenant de l'udénafil
TW200942524A (en) Novel aminomethyl benzene derivatives
MX2010001574A (es) Ligandos del receptor cannabinoide.
JO2831B1 (en) Quinclidine carbonate derivatives and pharmaceutical compounds
TW200942530A (en) Pyridine compounds
UA103025C2 (ru) Твердая композиция лекарственного средства замедленного высвобождения
EA200601759A1 (ru) Композиции рамиприла
MX2010000266A (es) Un método para disminuir los síntomas del consumo de alcohol.
MX2009010689A (es) Formulaciones novedosas para el suministro de agentes terapeuticos de peptidos antivirales.
IL191758A0 (en) Composition with sustained release of the active ingredient, process for the preparation thereof and use thereof